5 Key Takeaways

• 1

  Cryopreserved amniotic membrane (CAM) has become a primary treatment for dry eye disease (DED) and ocular surface diseases (OSDs).

• 2

  A retrospective study found that dry eye accounted for 44.2% of all sutureless amniotic membrane diagnosis claims in 2020 among Medicare patients.

• 3

  Corneal nerve damage significantly contributes to dry eye disease, affecting tear production, blink rate, and corneal wound healing.

• 4

  Studies indicate that CAM treatment improves signs and symptoms of DED, increases corneal nerve density, and enhances corneal sensitivity.

• 5

  The choice of amniotic membrane depends on individual patient factors, including corneal sensitivity and comorbid conditions like glaucoma.